ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
CLSA Downgrades ResMed (RMD:AU) (RMD) to Outperform (2), 'High near-term expectations may detract from long-term tailwinds'
August 15, 2022 6:31 AM EDTCLSA analyst Andrew Paine downgraded ResMed (RMD:AU) (NYSE: RMD) from Buy (1) to Outperform (2) with a price target of AUD38.40.
The analyst comments "ResMed (RMD) delivered another solid result in 4Q22, with revenues (ex-Covid at pcp) +10% CC to US$914.7m. This was in-line... More
JPMorgan Downgrades ResMed (RMD) to Neutral
August 12, 2022 9:38 AM EDTJPMorgan analyst David Low downgraded ResMed (NYSE: RMD) from Overweight to Neutral with a price target of $250.00 (from $255.00).
The analyst comments "ResMed is poised to take more market share over coming quarters as its device production ramps up and the key... More
ResMed (RMD) Tops Q4 EPS by 4c
August 11, 2022 4:08 PM EDTResMed (NYSE: RMD) reported Q4 EPS of $1.49, $0.04 better than the analyst estimate of $1.45. Revenue for the quarter came in at $914.7 million versus the consensus estimate of $910.54 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
... More